bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update Read more about bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
bluebird bio 2nd Quarter Results and Commercial Launch Progress Call Read more about bluebird bio 2nd Quarter Results and Commercial Launch Progress Call
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events Read more about bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
Goldman Sachs 44th Annual Global Healthcare Conference Read more about Goldman Sachs 44th Annual Global Healthcare Conference
BofA Securities 2023 Health Care Conference Read more about BofA Securities 2023 Health Care Conference
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events Read more about bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events